Format

Send to

Choose Destination
Int J Clin Pract. 2007 May;61(5):853-63. Epub 2007 Mar 16.

Dalbavancin: a novel antimicrobial.

Author information

1
Wayne State University School of Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, MI 48202, USA.

Abstract

The increasing incidence of serious infections because of Gram-positive pathogens and the rising cost in parenteral administration of antimicrobials has inspired the development of a novel antibiotic. Dalbavancin is the first once a week antibiotic with activity against a broad range of Gram-positive pathogens. A large multicentre, pivotal, Phase III clinical trial, which included 854 patients with complicated skin and skin structure infections, compared 1-2 doses of dalbavancin vs. linezolid. The results demonstrated non-inferiority and a comparable safety profile. With its unique pharmacokinetic profile, ease of use and excellent safety profile, dalbavancin should provide a valuable addition to the armamentarium used to treat infections because of Gram-positive cocci.

PMID:
17362476
PMCID:
PMC1890846
DOI:
10.1111/j.1742-1241.2007.01318.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center